# Retatrutide FAQ: 22 Common Questions Answered

> Retatrutide questions answered: FDA status, mechanism, how long it takes to work, half-life, differences from tirzepatide, and more. Sourced from the published clinical trial record.

## What is retatrutide (GGG tri-agonist / LY3437943) and what is its potential for treating obesity and diabetes?

Retatrutide (also called LY3437943 or the GIP/GLP-1/glucagon tri-agonist) is an investigational synthetic peptide developed by Eli Lilly that activates three hormone receptors simultaneously. In a 36-week Phase 2 trial in type 2 diabetes, 12 mg lowered HbA1c by −2.02% and reduced body weight by −16.94% versus placebo [2]. In a 48-week Phase 2 obesity trial, 12 mg produced −24.2% body weight change [1]. It is not approved by any regulator.

## What does retatrutide do?

Retatrutide activates GIP, GLP-1, and glucagon receptors simultaneously — suppressing appetite, improving glucose-dependent insulin secretion, and increasing energy expenditure. In Phase 2 obesity trials, this combination produced up to −24.2% body weight reduction at 48 weeks, and a 2025 review characterized this as a step-change versus earlier incretin-class agents [6]. It remains investigational and is not approved.

## How does retatrutide work?

Retatrutide is a triple agonist: it activates the GLP-1 receptor (appetite suppression, slowed gastric emptying, glucose-dependent insulin release), the GIP receptor (enhanced post-meal insulin secretion, adipose-tissue effects), and the glucagon receptor (increased energy expenditure and hepatic lipid metabolism) simultaneously. A 2025 mechanistic review explains how the glucagon arm adds energy-expenditure drive not achievable with GLP-1 or GIP agonism alone [9]. Cryo-EM structures confirm all three receptor dockings [3].

## How to reconstitute retatrutide?

There is no approved reconstitution protocol. Retatrutide has never been approved and has no FDA label. In clinical trials, it was a pharmaceutical-grade formulated injection prepared by Eli Lilly under GMP conditions — participants did not reconstitute it themselves. Gray-market lyophilized research powders are unverified substances with no confirmed identity, purity, or sterility, and outside all conditions under which the published safety data were generated. This site does not provide reconstitution guidance.

## Is retatrutide FDA approved?

No. Retatrutide is not approved by the FDA or any regulator as of mid-2026. It is in Phase 3 clinical trials (the TRIUMPH program) developed by Eli Lilly. Phase 3 trials are the large, late-stage trials that confirm efficacy and safety before a company can apply for regulatory approval. Until those trials complete and a regulatory application is reviewed and granted, retatrutide remains investigational.

## When will retatrutide be available?

No confirmed timeline exists. If the TRIUMPH Phase 3 program meets its primary endpoints and Eli Lilly files for FDA approval, and if the FDA grants that approval, retatrutide could become a prescription medicine. Approval is not guaranteed. As of mid-2026, Phase 3 trials are ongoing and no approval application has been submitted. Retatrutide availability as a prescription product remains a future possibility contingent on regulatory outcomes.

## How to take retatrutide?

In all completed clinical trials, retatrutide was administered as a once-weekly subcutaneous injection — injected into the fatty layer beneath the skin, typically in the abdomen, thigh, or upper arm [1, 2, 4]. Dose escalation (starting at a lower dose and gradually increasing) was used in trials to manage GI side effects. Retatrutide is not approved for any use outside clinical trials; this site does not provide administration guidance for non-clinical use.

## How long does retatrutide take to work?

In the Phase 2 obesity trial, meaningful weight reductions were observed within the first 8–12 weeks and continued through the 48-week trial period [1]. The qualitative exit-interview study found that 31 of 36 retatrutide-treated participants reported changes in eating behavior within the first 8 weeks, including reduced hunger and greater satiety [10]. A 2025 review notes the trajectory of weight loss as a distinguishing feature of the triple-agonist approach [6].

## Is retatrutide better than tirzepatide?

No head-to-head trial has completed and published results as of mid-2026. An active Phase 3 comparator trial is ongoing in the TRIUMPH program. Separately published Phase 2 data: tirzepatide produced approximately 20% weight loss in the SURMOUNT-1 trial over 72 weeks; retatrutide produced approximately 24% over 48 weeks in its Phase 2 obesity trial [1]. These are different trials with different populations and durations — direct comparison requires a completed head-to-head study.

## How much retatrutide per week?

In Phase 2 clinical trials, doses studied ranged from 1 mg to 12 mg once weekly via subcutaneous injection [1]. The 12 mg group showed the largest weight reductions. These are trial design facts — specific doses administered under controlled clinical conditions. Retatrutide is not approved, and these numbers are not dosing recommendations for non-clinical use.

## How to mix retatrutide with bacteriostatic water?

This question applies to lyophilized research-labeled peptides. There is no approved mixing protocol for retatrutide because it is not an approved product. In clinical trials, it was administered as a pre-formulated, pharmaceutical-grade injectable solution prepared by the manufacturer — not reconstituted by participants. Reconstituting any unverified research peptide in bacteriostatic water produces a substance of unknown identity and purity outside any clinical oversight. This site does not provide reconstitution or mixing instructions.

## How to switch from tirzepatide to retatrutide?

No published protocol exists for transitioning between these compounds, and such a transition would currently be impossible in a non-clinical context because retatrutide is not approved or available as a prescription product. No completed clinical trial has studied this question. Anyone currently using tirzepatide as a prescribed treatment for an approved indication should discuss any changes with their prescribing clinician.

## Is retatrutide a GLP-3?

No — "GLP-3" is a misnomer. There is no GLP-3 receptor. Retatrutide is a triple agonist at the GIP receptor, the GLP-1 receptor, and the glucagon receptor [1, 3]. The term "GLP-3" appears in some informal discussion and search queries but does not correspond to any identified hormone or receptor in the published pharmacology literature. Retatrutide is more accurately described as a GIP/GLP-1/glucagon receptor triagonist.

## Is retatrutide available?

Not commercially. Retatrutide is investigational and not approved anywhere. It is accessible only through active clinical trials. A gray market exists for research-labeled material, but such products are unregulated, of unverified identity and purity, and outside any clinical oversight. The FDA issued over 50 warning letters to retatrutide gray-market vendors in 2025. This site does not link to or endorse any vendors.

## What is retatrutide used for?

In clinical trials, retatrutide has been studied for obesity, type 2 diabetes, and MASLD (fatty liver disease). It has no approved indication anywhere in the world as of mid-2026. A 2025 review synthesizes the Phase 1/2 data across these indications and characterizes the triple-agonist approach as a promising investigational direction for metabolic disease [6]. "Used for" in a clinical sense awaits regulatory approval that has not occurred.

## What receptors does retatrutide target?

Retatrutide targets three receptors: the GLP-1 receptor (glucagon-like peptide-1 receptor), the GIP receptor (glucose-dependent insulinotropic polypeptide receptor), and the glucagon receptor (GCGR). Cryo-EM structural studies resolved the binding at each receptor at near-atomic resolution [3]. Its engineered relative potency is approximately 8.9x native GIP at the GIP receptor, 0.3x at the glucagon receptor, and 0.4x native GLP-1 at the GLP-1 receptor — an asymmetric profile designed to balance the benefits of glucagon agonism without excessive glucose elevation.

## Is retatrutide legal?

Retatrutide is not a controlled substance. It is an unapproved new drug under FDA jurisdiction. In the United States, selling or distributing an unapproved new drug in commerce is a violation of the Federal Food, Drug, and Cosmetic Act — which is why the FDA issued warning letters to gray-market vendors in 2025. Possession for personal research may not itself be illegal in all jurisdictions, but the legal landscape around investigational drugs varies by country and is beyond the scope of this editorial digest.

## How often do you take retatrutide?

In all clinical trials, retatrutide was administered once weekly by subcutaneous injection [1, 2, 4]. This dosing interval is supported by the approximately 6-day half-life established in the Phase 1b trial [4], which keeps the compound at meaningful concentrations between doses while allowing for once-weekly administration. Once-weekly is the only interval studied in the published trial record.

## What is the half-life of retatrutide?

Approximately 6 days, based on the Phase 1b first-in-human pharmacokinetic study [4]. This half-life is the result of retatrutide's engineered C20 fatty-diacid acylation, which enables the molecule to bind albumin (a carrier protein in blood), forming a slow-release depot that extends the half-life far beyond what the unmodified peptide would achieve. The 6-day half-life is the pharmacological rationale for once-weekly dosing.

## How to store retatrutide?

In clinical trials, retatrutide was stored and handled according to pharmaceutical-grade protocols established by Eli Lilly for GMP-formulated investigational material — temperature-controlled storage, light protection, and controlled sterility conditions. No approved storage standard exists for gray-market research preparations because they are not regulated products. This site does not provide storage guidance for non-clinical retatrutide.

## Is retatrutide the same as Ozempic?

No. Semaglutide is a GLP-1 receptor mono-agonist — it activates only one receptor. Retatrutide activates three (GIP, GLP-1, and glucagon receptors) simultaneously. They are structurally different molecules with different pharmacology and different development histories. Semaglutide is FDA-approved for type 2 diabetes and obesity management; retatrutide is investigational and not yet approved by any regulator.

## Is retatrutide better than semaglutide?

No head-to-head randomized controlled trial has compared retatrutide and semaglutide. Separately, Phase 2 data for retatrutide showed approximately 24% weight loss over 48 weeks in an obesity trial [1]; semaglutide's STEP 1 trial showed approximately 15% over 68 weeks. These are different trial designs, populations, and durations — direct comparison requires a completed comparative study. The mechanistic addition of GIP and glucagon agonism to GLP-1 agonism is the theoretical basis for expecting larger effects, but the trial evidence to definitively establish superiority in Phase 3 is pending.

---

An editorial reading of the Phase 1–3 retatrutide record — every figure walked back to its trial, with no clinic behind the reading room and nothing here prescribed or sold.